For over a decade we have explored the use of metathesis to generate peptides with enhanced potency, selectivity, plasma and physical stability. We have centred our attention on the replacement of native disulfide bridges due to their inherent in vivo instability and often problematic handling during solid phase synthesis. This led to the development of regioselective strategies for the formation of multiple dicarba bridges, the adoption of pseudoproline residues to promote ring closing metathesis (RCM), and new strategies for overcoming deleterious aggregation during catalysis.1 The generation of dicarba analogues of cystine-rich peptides can also be used to elucidate the unknown mechanism of action of a target peptide. Two notable examples from our laboratory investigating human insulin2 and a-conotoxins3 will be discussed. RCM on recombinant peptides, however, remains an undeveloped area. Genetic incorporation of non-proteinogenic allyl and crotyl glycine residues, inter alia, has been reported4 however the chemistry required to deal with the resultant highly polar, unprotected substrates has yet to be fully met. Oxytocin was used as a test substrate to develop methodology to facilitate protecting-group free olefin metathesis and our progress to date will be discussed.5 Our interest in metathesis has also extended into developing chemistry to achieve regioselective alkene cross metathesis (CM), with translation to a NàC polymerisation process, and more recently alkyne metathesis. Our latest results across these areas will be showcased.